Member Info for nlondon1234

I like this board.Shame the vote didn't work out.Did anybody ever figure out why Dodd just dropped it like a hot stone all of a sudden when he hadn't already lost?He could have at least waited for the official decision and given it a shot even if the timescale was short with getting 2/3 majority?Surely he knew that anyway.All that work just to give up yourself before the referee has blown the whistle.Just seemed a little incongruous.

I missed out on GGP at 0.7 because of lack of looking fundamentals and FARN from 80p.You have to assess your own risk - reward ratio.I don't have any other obligations with my portfolio so it is more venture.Any upside great, any downside no worries personally as i look after myself and can support myself elsewhere.

Yes.A slow increase based on multi-years r&d deveopment is better.

I'd focus on the science and growth potential, irrespective of anything else.That's where real value lies in any stock.Technical analysis might work for some stocks.

but the scientific studies here and in the us are really progressing and Gerard seems to be a real collaborator, realises the value of knowledge sharing and has worked on creating accretive value and realised the sometimes undervalued (at the time) value of R&D since he took over. And sometimes a bit of serendipity on your side and realising the opportunity, being in the right place with the right ip and tech at the right moment, doesn't go amiss too.

They're not shorting in the traditional sense.It's a hedge, which they don't want to close, but was partially reduced earlier this year in exchange for an equity position.They're caught out as such as now reluctant major bondholders in pmo and they didn't want this purchase to go through.

Still a few odd trades

I don't want to ramp but i like integumen (ticker skin).We're partnered with avacta to develop affirmers and modern water (mwg) with their microtox water tech and their years of water tech ip (our ceo is their chairman) and already have an ai business rinocloud which has had accurately detected e coli bacteria in water(https://www.labskin.co.uk/rinoclouds-ai-rawtest-a-resounding-success/).Check out Gerrard Brandon's twitter account the ceo.He's very informative.There is mounting evidence (studies lately) that's pointing towards wbe (water based epidemiology) being useful in tracking localised coronavirus breakouts.We're hoping to test the affirmers with sensors at aberdeen uni later this year and the ai tech addon and use them with the microtox boxes.It's a different covid play from the pharma one anyway.

always the day before there is a sudden, unusal increase in volume and buys.It is a good company nonetheless.

if you mean trading212 i would advise to stick to regular share purchases and don't try leveraged cfds.The stats show the majority lose money on them.That's why they legally have to put the warning up there now.The others who win, i'm supposing they are using algo trading bots or a more sophisticated system, like high frequency firms , than buy and hold.

Spread is certainly tightening all of a sudden.

Being a relatively large mcap company, they don't rely on 'pi' financing like some others on the bulletin boards.It was good you got an answer still though.

I think the pandemic and recession will work in favour of blue prism's automation software.

Warum haben wir die Börsennotiz in Frankfurt?;

It is great news isn't it and making vaccination delivery cheaper and more efficient after years of optimisation and studies on nuvec maybe we are right in the right sector at the right time too.Sometimes in life and business you need a bit of serendipity.

Hopefully will get news from avacta and the collab with our sensors soon, although science obviously takes time and with avacta's other projects on at the moment!

Positive in-vitro news with the covid plasmid work.

Great news.Years of tireless work and refinements of nuvec starting to pay dividends.

Seen a bunch of them in another share's trades too lately.Thought is its trade212, robinhood type brokers.Weird though that these shares aren't BP or Apple or big companies the general public have heard of.

Hopefully good news.I believe that Evotec wouldn't taken the project on if it didn't have a good chance to replicate previous testing successes with the covid plasmids.Nuvec has already been proven to be able to load and deliver multiple plasmids.So it has already shown superior manufacture of viral vectors to current marketed competitors and thus at a lower cost per vaccination.